The Brand Name FENOFIBRIC Has Generic Salt :: Fenofibrate 

FENOFIBRIC  Is From Company DELVIN Priced :: Rs. 69

FENOFIBRIC have Fenofibrate is comes under Sub class Anti Hyperlipidemics of  Main Class Cardiovascular System

Main Medicine Class:: Cardiovascular System  Sub Medicine Class :: Anti Hyperlipidemics 

Indications for Drugs ::

Hyperlipidemia,Hypercholesterolaemia,Hypertriglyceridaemia

Drug Dose ::

Adult: PO : Standard micronised formulation: Initially, 200 mg once daily. For non-micronised formulations: Initial: 200-300 mg/day in divided doses. Usual range: 200-400 mg/day. Formulation w/ improved bioavailability: 40-160 mg once daily may be used.

Contraindication ::

Hypersensitivity; severe hepatic and renal impairment. Unexplained persistent liver function abnormality and primary biliary cirrhosis; preexisting gall bladder disease. Pregnancy, lactation.

Drug Precautions ::

Renal or hepatic impairment. Monitor LFTs and blood counts regularly. Increased risk of cholelithiasis, pancreatitis, skeletal muscle effects. Withdraw treatment if no adequate response after 2 mth of treatment at max recommended dose.

Drug Side Effects ::

Headache, dizziness, asthaenia, fatigue, arrhythmia, photosensitivity, eczema, dizziness, vaginitis, paraesthesia, rhinitis, cough, sinusitis, allergic pulmonary alveolitis, polyuria, myopathy, myositis, arthralgia, myalgia, myasthenia. Potentially Fatal: Hepatitis, cholecystitis.

Pregnancy category ::

3

Drug Mode of Action ::  

Fenofibrate, a fibric acid derivative, lowers plasma triglyceride by activating lipoprotein lipase thus increasing catabolism of VLDL w/ consequent increase in HDL levels.

Drug Interactions ::

Decreased absorption w/ bile acid sequestrants (e.g. colestyramine). May increase risk of ciclosporin-induced nephrotoxicity. Increased risk of muscle toxicity w/ HMG-CoA reductase inhibitors (e.g. simvastatin). May increase risk of bleeding w/ oral anticoagulants.